Recordati's Remarkable Financial Performance in Q1 2025
Recordati S.p.A., recognized for its milestone achievements in the pharmaceutical sector, has unveiled its impressive financial performance for the first quarter of 2025. The company reported consolidated net revenue of €680.0 million, marking a stunning 11.9% increase compared to the previous year. This figure also reflects a solid 7.2% growth on a like-for-like basis when adjusted for constant exchange rates.
Strong EBITDA and Net Income Growth
The company’s EBITDA for the first quarter reached €270.2 million, showcasing a robust growth of 10.7% and achieving a remarkable margin of 39.7% on revenue. Meanwhile, adjusted net income also saw significant growth at €175.5 million, which is up by 7.2% from the prior year. Overall, Recordati’s net income showed a modest rise to €125.0 million, which is a 1.2% increase compared to the same period last year.
Cash Flow and Debt Management
In terms of cash flow, Recordati reported a free cash flow of €158.8 million, indicating a positive trend driven primarily by the enhanced EBITDA. Additionally, the company's net debt totaled €2,020.8 million, positioned at just below 2.2x EBITDA pro-forma, demonstrating the firm's effective management of financial leverage.
Product Developments and Regulatory Approvals
Recordati continues to enhance its product portfolio with the recent expanded approval by the FDA for Isturisa®, focusing on treating endogenous hypercortisolemia in adults with Cushing’s syndrome. This approval is anticipated to boost peak year sales, projected to reach between €550 million and €650 million. Furthermore, the approval of Signifor® LAR in China for treating patients with acromegaly underlines the company’s commitment to expanding its Rare Diseases portfolio.
Strategic Outlook and Financial Targets
In light of the robust start to 2025, Recordati has reaffirmed its financial targets for the fiscal year, forecasting net revenue between €2,600 million and €2,670 million. The projections also outline an EBITDA range of €970 million to €1,000 million, which translates to a margin of approximately 37.5%. Adjusted net income expectations for fiscal year 2025 are positioned between €640 million to €670 million with a margin close to 25%.
Long-Term Goals for 2027
Recordati's forward-looking three-year plan indicates a commitment to sustained growth, expecting net revenue to reach between €3,000 million to €3,200 million by 2027. The projected EBITDA for 2027 is slated to be between €1,140 million and €1,225 million, with anticipated profit margins exceeding 38%.
Commitment to Shareholder Value
The company also maintains a progressive dividend policy, indicating its confidence in ongoing business strength and cash generation capabilities. This commitment reflects an intent to enhance shareholder value while comfortably navigating investment opportunities.
Frequently Asked Questions
What was Recordati's net revenue for Q1 2025?
Recordati reported a consolidated net revenue of €680.0 million for the first quarter of 2025, which represents an 11.9% increase year-over-year.
How much did Recordati's EBITDA grow in Q1 2025?
The EBITDA for Recordati reached €270.2 million in Q1 2025, a significant increase of 10.7% compared to the previous year.
What are the anticipated sales projections for Isturisa®?
Projected peak year sales for Isturisa® are expected to be between €550 million and €650 million following its recent FDA approval for expanded indications.
What are the financial targets set for FY 2025?
Recordati has set its financial targets for FY 2025 to achieve net revenue between €2,600 million and €2,670 million, with EBITDA in the range of €970 million to €1,000 million.
How is Recordati ensuring long-term growth?
Recordati’s strategy includes a comprehensive three-year plan targeting net revenue growth to €3,000 million to €3,200 million by 2027, alongside significant EBITDA improvements.
